Samsung Bioepis Projected to Reach 1.4 Trillion KRW in Sales
Samsung Bioepis has surpassed its total annual revenue from last year within the first three quarters of 2023.…
biosimilar
2 개의 기사가 있습니다.
Samsung Bioepis’ Autoimmune Disease Treatment ‘PYZCHIVA’ Approved in the U.S.
Samsung Bioepis has announced that its biosimilar to Stelara, named ‘Pyzchiva’ (project name SB17, active ingredient ustekinumab), has…